A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors
LB101-101
Phase 2 other active
Quick answer
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors for Advanced solid tumors is a Phase 2 program (other) at Centessa Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Centessa Pharmaceuticals plc
- Indication
- Advanced solid tumors
- Phase
- Phase 2
- Modality
- other
- Status
- active